Avonex Articles
Ares-Serono 1sr qtr net income leaps 39.2%
28 April 2000
Inhale developing pulmonary Avonex
19 April 2000
Stock Commentary New York
19 April 2000
Serono "almost perfect biotech investment"
10 March 2000
Biogen looking at German acquisitions
6 March 2000
Management changes at Biogen
2 March 2000
Serono to seek changes to Rebif label
2 March 2000
Analysts enthuse about Ares-Serono
4 February 2000
Ares-Serono sales hit $1 billion mark
19 January 2000
Biogen starts Phase III trials of Amevive in plaque psoriasis
6 December 1999
Ares-Serono says sales "on track to exceed $1 billion in 1999"
4 November 1999
Biogen halts Antova trials, citing serious adverse events
26 October 1999
Biogen earnings rise 65% for third quarter
11 October 1999
Head-to-head Avonex, Rebif trial in MS initiated
11 October 1999
Biogen Nordic operations, R&D center in USA
8 October 1999
Biogen expects higher 3rd quarter earnings, driven by Avonex
22 September 1999
Biogen expects strong growth in third quarter
17 September 1999
Biogen claims Avonex ahead of Betaferon
22 July 1999
Rebif for secondary progressive MS
10 June 1999
1st qtr net income up 111% at Ares-Serono
30 April 1999
New Rebif dosage approved by EU
15 April 1999
Record 1st qtr sales and earnings at Biogen
13 April 1999
Ares-Serono's earnings beat expectations
11 March 1999
Stock Commentary New York
4 March 1999
Serono rebuffed over Rebif claims in USA
25 February 1999
PowderJect to deliver Serono drugs
11 February 1999
First secondary-progressive MS drug for EU
2 February 1999
Swiss approve Ares-Serono's Rebif
21 January 1999
Stock Commentary New York
20 January 1999
Ares-Serono posts solid growth in 1998
19 January 1999
Avonex gives Biogen record revenues
18 January 1999
New Rebif dose backed
14 January 1999
Busy end to 1998 for Biogen as CEO resigns
5 January 1999
Mitoxantrone Filing For MS In Second-Quarter '99?
8 December 1998
Correction
8 December 1998
Advances In CNS Therapeutics Reviewed By Lehman Analysts
30 November 1998
Analysts Back Rebif And Upgrade Serono
26 November 1998
Disappointing Results For Ares-Serono
12 November 1998
Betaferon Backed For Progressive MS
28 October 1998
Biogen Opposes Rentschler's Beta Interferon Patent
19 October 1998
Biogen 3rd Qtr Sales And Profits Pushed By Avonex
7 October 1998
German Court Moves On Inaccurate Avonex Info By Schering AG
25 September 1998
Sales Fall But Profits Rise At Ares-Serono
18 August 1998
Avonex Drives 57% Earnings Growth At Biogen
14 July 1998
Euro CPMP April Plenary Meeting
18 June 1998
Investors Falling Out Of Love With Teva?
19 May 1998
EMEA Approves Ares-Serono's Rebif For MS
7 May 1998
Broker Assesses Ares-Serono Results
21 April 1998
Sales Fall But Profits Rise At Ares-Serono
16 April 1998
Biogen Posts Strong Sales Rise For 1st Quarter
15 April 1998
Good Prospects For Ares-Serono's Rebif?
26 March 1998
European Stock Comment
12 March 1998
Ares-Serono Earnings Jump 64% For 1997
3 March 1998
Biogen To Establish Canadian Operation
23 February 1998
Rebif Roll-Out Continues, Next Market Canada
19 February 1998
Stock Commentary New York
19 February 1998
Betaferon Effective In Secondary Progressive MS
11 February 1998
Schering AG To Stay Independent As Sales Grow
9 February 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
Stock Commentary New York
29 January 1998
Record 4th Qtr & 1997 Results For Biogen
16 January 1998
Strong $ Hits Ares-Serono's European Growth
16 January 1998
US Orphan Drug Program: Global Reference Point
18 December 1997
Biogen & Merck Sign $130 Million Deal
4 December 1997
Apotex Sets Up Italian Generics Company
4 December 1997
New York Stock Comment
23 October 1997
Avonex Boosts 3rd Qtr Growth At Biogen
15 October 1997
First Approval Of Geref As Therapeutic
9 October 1997
Serono Poised To Enter Multiple Sclerosis Fray
8 October 1997
Biogen Shares Move On Analyst's Ratings
11 September 1997
Biogen-Schering Battle Over MS German Market
8 September 1997
Avonex Growth In Second Qtr At Biogen
15 July 1997
Serono Joins US Interferon Litigation
30 May 1997
Biogen Welcomed To Research Triangle Park
26 May 1997
Higher Biotech Earnings But Investors Stay Cool
19 May 1997
Biogen Returns To First-Quarter Profit
21 April 1997
EPO Revokes Biogens rIFN beta Patent
10 April 1997
Copaxone Launched In The USA, Its Second Market
9 April 1997
Wall Street Disappointment With Biogen Hits Teva
26 March 1997
Schering Upbeat On 1997 Following Strength In 1996
20 March 1997
Biogen Receives EU Approval For Avonex
19 March 1997
Schering AG Posts 13% Sales Hike For 1996
17 February 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
